| 1/4 | US=9 / Urologia Ning YM, Dagher RN, Pazdur R. FDA approval of prostate cancer treatments. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 399-405. ISBN 978-1-60327-831-7. FDA DOS TRATAMENTOS DO CANCER DE PROSTATA; APROVACAO DE MEDICAMENTOS; DESENVOLVIMENTO DE MEDICAMENTOS; ENDPOINTS; FDA; ANALISE POST-HOC; CANCER DE PROSTATA; ANALISE DE SUBGRUPO; PARAMETROS DE SUBSTITUICAO; SOBREVIVENCIA |
| 2/4 | US=28 / Biol/Mol Eder JP, Zuckerman DS. Endpoints for the determination of efficacy of antiangiogenic agents in clinical trials. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 509-24. ISBN 978-1-58829-870-6. |
| 3/4 | US=80 / Biol/Mol Alaoui-Jamali MA, Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 59-77. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. TIROSINA-QUINASES PROTEICAS; CANCER; TERAPIA-ALVO; PROTEOMICA |
| 4/4 | US=58 / Biol/Mol McConville P, Elliott WL, Kreger A, Lister R, Moody JB, Trachet E, Urban F, Leopold WR. Preclinical models of tumor growth and response. In: Shields AF, Price P. In vivo imaging of cancer therapy. New Jersey: Humana Press, 2007. p. 13-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-633-7. CRESCIMENTO DO TUMOR; RESPOSTA DO TUMOR; TIPOS DE MODELOS DE TUMORES; ENDPOINTS; MEDICOES; CARGA TUMORAL |